17 posts tagged licensing from Commercializing Science.
Minimum annual royalty clauses are meant to protect universities from dormant licenses, but most are drafted in ways that undermine both parties from the start.
A. KovacsAudit rights in license agreements are among the most valuable and most neglected tools in technology transfer. Here's why that keeps costing universities money.
A. KovacsRoyalty stacking provisions look like licensee protection but often destroy deal economics. Here's what universities get wrong and how to fix it.
A. KovacsBayh-Dole compliance at most universities is a defensive legal exercise. Here's why that posture quietly destroys commercialization potential.
A. KovacsMost patent claims are drafted to survive examination, not to support licensing deals. Here's what gets lost when prosecution strategy ignores commercial reality.
A. KovacsReach-through royalty provisions look like smart IP protection but routinely kill university-industry deals. Here's what to do instead.
A. KovacsMost invention valuation methods in tech transfer generate figures that satisfy spreadsheets but fail negotiations. Here's what actually works.
A. KovacsMost license milestone structures protect universities from inaction but accidentally punish real development progress. Here's what to do instead.
A. KovacsSublicensing provisions in university license agreements often hand control to licensees by default. Here's what to negotiate before it's too late.
A. KovacsMost university patent prosecution focuses on legal coverage, not commercial timing. Here's why that mismatch quietly kills licensing deals before they start.
A. KovacsMost tech transfer royalty negotiations anchor on industry averages and gut feel. Here's why that produces bad deals and what to use instead.
A. KovacsMTAs look like administrative paperwork, but buried clauses routinely strip universities and startups of the IP rights they need to commercialize research.
A. KovacsField-of-use restrictions in university license agreements promise focused commercialization but routinely strangle deal value and block better applications from reaching market.
A. KovacsExclusive licenses feel like wins for everyone at signing. Here's why they quietly kill commercialization, and what to structure instead.
A. KovacsOption agreements should de-risk early licensing deals, but most TTOs use them wrong. Here's what's broken and how to fix it.
A. KovacsMost university licensing deals collapse not because of bad science or bad intent, but because of preventable negotiation failures. Here's what actually goes wrong.
A. Kovacs